Erin E. Mulvihill, PhD, is a Scientist and Director of the Energy Substrate Metabolism Research Laboratory at the University of Ottawa Heart Institute. She is also an Associate Professor, Department of Biochemistry, Microbiology and Immunology, in the Faculty of Medicine, at the University of Ottawa.
Dr. Erin Mulvihill obtained her PhD in Biochemistry from the University of Western Ontario under the supervision of Murray Huff, PhD, in the Vascular Biology Group at the Robarts Research Institute. During her doctoral studies, Dr. Mulvihill’s work focused on understanding how therapeutic interventions can target hepatic lipoprotein production and prevent the formation of atherosclerotic lesions.
Dr. Mulvihill completed postdoctoral training under the supervision of Dr. Daniel Drucker, a notable leader in the fields of incretin biology and Type 2 Diabetes at the Lunenfeld-Tanenbaum Research Institute, located at Mount Sinai Hospital. During her postdoctoral tenure, Dr. Mulvihill led a detailed molecular assessment of how DPP4 inhibitors lower blood glucose using a combination of mouse genetics and pharmacology. She has also been involved in understanding how incretin therapies impact cardiovascular disease using several genetic mouse models. She was awarded a Lunenfeld-Tanenbaum Research Institute Innovation Grant in 2016.
Dr. Mulvihill joined the University of Ottawa and University of Ottawa Heart Institute in July 2017. Her program is funded by the Canadian Institutes of Health Research, Diabetes Canada, Heart and Stroke foundation, the Natural Sciences and Engineering Council of Canada, the Diabetes Merck Investigator Studies Program, and the Canada Foundation for Innovation.
Recognition and awards:
- Heart and Stroke National New Investigator Award
- CIHR New Investigator Award
- Diabetes Canada New Investigator Award
- Amgen Steward Whitman Canada Lipoprotein Conference New Investigator Award
Dr. Mulvihill has expertise in lipids and lipoproteins, models of diabetes and cardiovascular disease, intestinal biology and mouse genetics. Her research program contributes to improving our understanding of the molecular events which contribute to metabolic and cardiovascular disease.
- Morrow NM, Locatelli CAA, Hanson AA, Imran S, and Mulvihill EE. (2022). Adaptation to Short-term Extreme Fat Consumption Alters Intestinal Lipid Handling in Male and Female mice. BBA - Molecular and Cell Biology of Lipids.
- dos Santos T, Galipeau M, Schukarucha Gomes A, Lee D, Maghera J, Perera I, Polischevska K, Shayeganpour K, van Allen K, Wang Y, Greenberg M, Larsen M, Mulchandani C, Patton M, Ramdass S, Vafaeian K, Weisz T, Estall JL, Mulvihill EE, Screaton RA. (2022) Islet Biology Advances during COVID-19: Progress and Perspectives. Canadian Journal of Diabetes
- Morrow NM, Trzaskalski NA, Hanson, AA, Fadzeyeva E, Telford DE, Choker S, Sutherland BG, Edwards JY, Huff MW, Mulvihill EE. (2022). Nobiletin Prevents High-fat diet induced Dysregulation of Intestinal Lipid Metabolism and Attenuates Post-prandial Lipemia. Arteriosclerosis, Thrombosis, and Vascular Biology. 42(2): 127-144.
- Ussher JRU, Greenwell A, Nguyen MA, Mulvihill EE. (2022). Cardiovascular Actions of Incretin Based Therapies: Integrating Mechanisms with Cardiovascular Outcomes Trials. Diabetes. 71(2): 173-183.
- Dann MM, Clark SQ, Trzaskalski NA, Earl CC, Schepers LE, Pulente SM, Lennord EN, Annamalai K, Gruber JM, Cox AD, Lorenzen-Schmidt I, Seymour R, Kim KH, Goergen CJ, Mulvihill EE. (2022) Quantification of Murine Myocardial Infarct Size using 2D and 4D Ultra-High Frequency Ultrasound. American Journal of Physiology - Heart and Circulatory Physiology. 322(3): H359-H372.
- Varin EM*, Mulvihill EE*, Baggio LL, Koehler J, Cao X, Seeley R, Drucker DJ. Distinct neural sites of GLP-1R expression mediate physiological vs. pharmacological control of incretin action. Cell Reports. 2019; 27: 3371–3384. (*Authors contributed equally).
- Varin EM*, Mulvihill EE*, Beaudry JL, Pujadas G, Fuchs S, Tanti Fazio JF, Kaur K, Matthews D, Baggio LL, Campbell JE, Drucker DJ. Hepatocyte-derived dipeptidyl peptidase 4 controls obesity-associated inflammation but not glucose homeostasis. Cell Metabolism. 2019; 29: 320-334. (*Authors contributed equally).
- Ussher JR, Campbell JE, Mulvihill EE, Baggio LL, Bates HE, Gopal K, Lamont BJ, Ilkayeva O, Ali S, Kim M, Kabir MG, Seino Y, Newgard CB, Suzuki J, Drucker DJ. Inactivation of the Glucose-Dependent Insulinotropic Peptide Receptor Improves Outcomes Following Experimental Myocardial Infarction. Cell Metabolism. 2018; 2: 450-460.
- Mulvihill EE*, Varin EM*, Gladanac B, Campbell JE, Ussher JR, Baggio LL, Ayala J, Burmeister M, Yusta B, Holland D, Bang AKW,, Casper R, Ayala JE, Drucker DJ. Cellular ablation of Dpp4 reveals mechanism of glucose control. Cell Metabolism. 2017; 25(1): 152-165. (*Authours contributed equally)